Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials-Reference-Cited by-同舟云学术

Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials

Published:2019-06-04 Issue: Volume:6 Page:
ISSN:2296-858X
Container-title:Frontiers in Medicine
language:
Short-container-title:Front. Med.

Author:

Paller Channing J.,Huang Erich P.,Luechtefeld Thomas,Massett Holly A.,Williams Christopher C.,Zhao Jinxiu,Gravell Amy E.,Tamashiro Tami,Reeves Steven A.,Rosner Gary L.,Carducci Michael A.,Rubinstein Lawrence,Ivy S. Percy

Funder

National Institutes of Health

Publisher

Frontiers Media SA

Subject

General Medicine

Reference23 articles.

1. Next-generation sequencing in drug development: target identification and genetically stratified clinical trials;Torshizi;Drug Discov Today.,2018

2. Strategies for modern biomarker and drug development in oncology;Smith;J Hematol Oncol.,2014

3. Novel technologies and emerging biomarkers for personalized cancer immunotherapy;Yuan;J Immunother Cancer.,2016

4. Approaches to modernize the combination drug development paradigm;Day;Genome Med.,2016

5. Characteristics of drug combination therapy in oncology by analyzing clinical trial data on ClinicalTrials;Wu;Pac Symp Biocomput.,2014

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors;npj Systems Biology and Applications;2024-06-21

2. Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA Damage Response inhibitors;2023-11-21

3. Discovery and development of botanical natural products and their analogues as therapeutics for ovarian cancer;Natural Product Reports;2023

4. A rationale for dedicated trials of combination therapy in heart failure;European Heart Journal Supplements;2022-12-19

5. 2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory Inputs (Part 1A – Recommendations on Endogenous Compounds, Small Molecules, Complex Methods, Regulated Mass Spec of Large Molecules, Small Molecule, PoC & Part 1B - Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine);Bioanalysis;2022-05